Tag: ECHELON-2
ASH 2020: ECHELON-1 and ECHELON-2 and other Results with Brentuximab Vedotin
Presentations discussing brentuximab vedotin (Adcetris®; Seagen/Takeda) presented during the 62nd American Society of Hematology (ASH) Annual, Meeting, and Exposition, held virtually from December 5...
Long-term Data of Brentuximab Vedotin Redifines Treatment of Frontline Mature T-Cell...
Data highlighted at the 59th annual meeting of the American Society of Hematology (ASH) held in Atlanta, Georgia, December 9-12, 2017 shows final five-year...
Patient Enrollment in Phase III ECHELON-2 Clinical Trial of Brentuximab Vedotin...
This week, Seattle Genetics and Takeda Pharmaceutical Co. confirmed that enrollment in the ECHELON-2 clinical trial, a global phase III randomized trial evaluating brentuximab vedotin...
Alcanza Trial Demonstrates Highly Statistically Significant Improvement in Rate of Objective...
Results of the phase III Alcanza trial evaluating brentuximab vedotin (Adcetris®; Takeda Pharmaceutical and Seattle Genetics) in patients with cutaneous T-cell lymphoma (CTCL) shows...
European Commission Approves Brentuximab Vedotin for Consolidation Treatment in Post-Transplant Hodgkin...
The European Commission (EC) has extended the current conditional marketing authorization of brentuximab vedotin (Adcetris®/Seattle Genetics/Takeda Oncology) and approved the drug for the treatment of...
Improving Hodgkin Lymphoma Treatment: Brentuximab Vedotin Data Supports Foundation of...
Final pivotal trial results in relapsed/refractory Hodgkin lymphoma (HL) demonstrate durable remissions lasting more than five years after brentuximab vedotin (Adcetris®; Seattle Genetics) monotherapy. Oral...
